

# Per-Ola Andersson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7821812/publications.pdf>

Version: 2024-02-01

23  
papers

444  
citations

759233

12  
h-index

752698

20  
g-index

24  
all docs

24  
docs citations

24  
times ranked

903  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. <i>Haematologica</i> , 2017, 102, 1683-1690.	3.5	65
2	Reduced transforming growth factor- $\beta$ 1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2002, 116, 862-867.	2.5	54
3	High-Sensitivity Troponins and Outcomes After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2616-2624.	2.8	47
4	Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL. <i>Clinical Epigenetics</i> , 2016, 8, 106.	4.1	45
5	The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma—a population-based study. <i>Leukemia and Lymphoma</i> , 2007, 48, 736-745.	1.3	37
6	Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. <i>Blood Cancer Journal</i> , 2021, 11, 9.	6.2	32
7	Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 1020-1028.	4.1	23
8	Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. <i>Leukemia and Lymphoma</i> , 2012, 53, 394-399.	1.3	22
9	Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients—a pilot study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1814-1822.	1.3	16
10	Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimeric antigen receptor T cell eligibility criteria in second line—a population-based study of 736 patients. <i>British Journal of Haematology</i> , 2022, 198, 267-277.	2.5	16
11	SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients. <i>International Journal of Proteomics</i> , 2015, 2015, 1-12.	2.0	15
12	Global distribution of DNA hydroxymethylation and DNA methylation in chronic lymphocytic leukemia. <i>Epigenetics and Chromatin</i> , 2019, 12, 4.	3.9	15
13	Low response rate to ATG-based immunosuppressive therapy in very severe aplastic anaemia—a Swedish nationwide cohort study. <i>European Journal of Haematology</i> , 2018, 100, 613-620.	2.2	13
14	Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients. <i>British Journal of Haematology</i> , 2018, 181, 770-781.	2.5	12
15	Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study. <i>British Journal of Haematology</i> , 2021, 193, 906-914.	2.5	12
16	High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival and Similar Outcome of Related and Unrelated Allogeneic Stem Cell Transplantation for Aplastic Anemia: A Nationwide Swedish Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1970-1974.	2.0	11
17	Serum metabolomic profiling correlated with ISS and clinical outcome for multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. <i>Experimental Hematology</i> , 2021, 97, 79-88.e8.	0.4	5
18	TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2595-2604.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden. <i>Blood</i> , 2018, 132, 2975-2975.	1.4	1
20	Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden. <i>Blood</i> , 2020, 136, 38-39.	1.4	1
21	Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-14.	1.3	0
22	Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden. <i>Blood</i> , 2019, 134, 399-399.	1.4	0
23	Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden. <i>Blood</i> , 2020, 136, 46-47.	1.4	0